Dow Inc vs Illumina, Inc. — how do they compare? Dow Inc trades at $28.5 (market cap $20.65B), while Illumina, Inc. trades at $265.01 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.9% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Illumina, Inc. for 83 Days on average.
| DOW | ILMN | |
|---|---|---|
Market Cap | $20.65B | $39.95B |
Volume | 14,126,943 | 3,169,503 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $293.69 |
52-Week Low | $20.65 | $91.00 |
Typical Hold Time | 82 Days | 83 Days |
Enterprise Value | $36.34B | $41.31B |
Dividend Yield | 4.9% | — |
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%) despite beating recent EPS estimates. Revenue declined from $56.9B in 2022 to $40.0B in 2025, though 2026 projections show modest recovery to $41.3B. Analyst consensus is mixed with 28% buy ratings but a $34.22 price target suggesting 23% upside potential from current levels.
DOW presents a high-risk opportunity with significant valuation disconnect. While technicals are bearish and profitability metrics weak, the stock trades at attractive valuation multiples (P/S: 0.5x, P/B: 1.3x) with dividend support. Key risks include ongoing margin pressure, declining operating cash flow trend, and rising debt-to-asset ratio approaching 30%. The investment case hinges on earnings recovery and operational turnaround execution.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →